These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 38708541)

  • 21. [Long-term efficacy of encorafenib plus binimetinib combined treatment: case report.].
    Spagnolo F
    Recenti Prog Med; 2021 Apr; 112(4):49e-52e. PubMed ID: 33877100
    [TBL] [Abstract][Full Text] [Related]  

  • 22. COLUMBUS 5-year update: a randomized, open-label, phase III trial of encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF.
    Dummer R; Flaherty KT; Robert C; Arance A; B de Groot JW; Garbe C; Gogas HJ; Gutzmer R; Krajsová I; Liszkay G; Loquai C; Mandalà M; Schadendorf D; Yamazaki N; Pietro AD; Cantey-Kiser J; Edwards M; Ascierto PA
    Future Oncol; 2023 May; 19(16):1091-1098. PubMed ID: 37309702
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Encorafenib and binimetinib for the treatment of BRAF-mutated metastatic melanoma in the setting of combined hepatic and renal impairment.
    Ngo P; Bycroft R
    BMJ Case Rep; 2019 Sep; 12(9):. PubMed ID: 31527213
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The discovery and development of binimetinib for the treatment of melanoma.
    Tran B; Cohen MS
    Expert Opin Drug Discov; 2020 Jul; 15(7):745-754. PubMed ID: 32249628
    [TBL] [Abstract][Full Text] [Related]  

  • 25. COLUMBUS 5-Year Update: A Randomized, Open-Label, Phase III Trial of Encorafenib Plus Binimetinib Versus Vemurafenib or Encorafenib in Patients With
    Dummer R; Flaherty KT; Robert C; Arance A; de Groot JWB; Garbe C; Gogas HJ; Gutzmer R; Krajsová I; Liszkay G; Loquai C; Mandalà M; Schadendorf D; Yamazaki N; di Pietro A; Cantey-Kiser J; Edwards M; Ascierto PA
    J Clin Oncol; 2022 Dec; 40(36):4178-4188. PubMed ID: 35862871
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Encorafenib plus binimetinib in patients with
    Riely GJ; Ahn MJ; Felip E; Ramalingam SS; Smit EF; Tsao AS; Alcasid A; Usari T; Wissel PS; Wilner KD; Johnson BE
    Future Oncol; 2022 Mar; 18(7):781-791. PubMed ID: 34918546
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Case series of BRAF-mutated advanced melanoma treated with encorafenib plus binimetinib combination therapy.
    Fujimura T; Yoshino K; Kato H; Fujisawa Y; Nakamura Y; Yamamoto Y; Kunimoto K; Ito T; Matsushita S; Maekawa T; Ohuchi K; Amagai R; Muto Y; Furudate S; Kambayashi Y; Hashimoto A; Aiba S
    J Dermatol; 2021 Mar; 48(3):397-400. PubMed ID: 33179310
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Development of encorafenib for BRAF-mutated advanced melanoma.
    Koelblinger P; Thuerigen O; Dummer R
    Curr Opin Oncol; 2018 Mar; 30(2):125-133. PubMed ID: 29356698
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Encorafenib, Binimetinib, and Cetuximab in
    Kopetz S; Grothey A; Yaeger R; Van Cutsem E; Desai J; Yoshino T; Wasan H; Ciardiello F; Loupakis F; Hong YS; Steeghs N; Guren TK; Arkenau HT; Garcia-Alfonso P; Pfeiffer P; Orlov S; Lonardi S; Elez E; Kim TW; Schellens JHM; Guo C; Krishnan A; Dekervel J; Morris V; Calvo Ferrandiz A; Tarpgaard LS; Braun M; Gollerkeri A; Keir C; Maharry K; Pickard M; Christy-Bittel J; Anderson L; Sandor V; Tabernero J
    N Engl J Med; 2019 Oct; 381(17):1632-1643. PubMed ID: 31566309
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A Practical Review of Encorafenib and Binimetinib Therapy Management in Patients with BRAF V600E-Mutant Metastatic Non-Small Cell Lung Cancer.
    Baik C; Cheng ML; Dietrich M; Gray JE; Karim NA
    Adv Ther; 2024 Jul; 41(7):2586-2605. PubMed ID: 38698170
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Phase II, Open-Label Study of Encorafenib Plus Binimetinib in Patients With
    Riely GJ; Smit EF; Ahn MJ; Felip E; Ramalingam SS; Tsao A; Johnson M; Gelsomino F; Esper R; Nadal E; Offin M; Provencio M; Clarke J; Hussain M; Otterson GA; Dagogo-Jack I; Goldman JW; Morgensztern D; Alcasid A; Usari T; Wissel P; Wilner K; Pathan N; Tonkovyd S; Johnson BE
    J Clin Oncol; 2023 Jul; 41(21):3700-3711. PubMed ID: 37270692
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Complete response to encorafenib plus binimetinib in a
    Arregui M; Calles A; Galera MDM; Gutiérrez A; López-Jiménez C; Agra C; Fernández A; Gutiérrez N; Toro M; Álvarez R
    Oncotarget; 2024 Oct; 15():717-724. PubMed ID: 39392364
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Sequencing of Checkpoint or BRAF/MEK Inhibitors on Brain Metastases in Melanoma.
    Ascierto PA; Mandalà M; Ferrucci PF; Guidoboni M; Rutkowski P; Ferraresi V; Arance A; Guida M; Maiello E; Gogas H; Richtig E; Quaglino P; Lebbé C; Helgadottir H; Queirolo P; Spagnolo F; Tucci M; Del Vecchio M; Gonzalez-Cao M; Minisini AM; De Placido S; Sanmamed MF; Casula M; Bulgarelli J; Pisano M; Piccinini C; Piccin L; Cossu A; Mallardo D; Paone M; Vitale MG; Melero I; Grimaldi AM; Giannarelli D; Palmieri G; Dummer R; Sileni VC
    NEJM Evid; 2024 Oct; 3(10):EVIDoa2400087. PubMed ID: 39315864
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Complete response of brainstem metastasis in BRAF-mutated melanoma without stereotactic radiosurgery after initiation of encorafenib and binimetinib.
    Khullar K; Hanft S; Mehnert JM; Weiner JP
    Melanoma Res; 2021 Aug; 31(4):393-396. PubMed ID: 34054058
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Preclinical discovery and clinical development of encorafenib for the treatment of melanoma.
    Okten IN; Ismail S; Withycombe BM; Eroglu Z
    Expert Opin Drug Discov; 2020 Dec; 15(12):1373-1380. PubMed ID: 32720533
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Encorafenib plus cetuximab with or without binimetinib in patients with BRAF V600E-mutated metastatic colorectal cancer: real-life data from an Italian multicenter experience.
    Boccaccino A; Borelli B; Intini R; Antista M; Bensi M; Rossini D; Passardi A; Tamberi S; Giampieri R; Antonuzzo L; Noto L; Roviello G; Zichi C; Salati M; Puccini A; Noto C; Parisi A; Rihawi K; Persano M; Crespi V; Libertini M; Giordano M; Moretto R; Lonardi S; Cremolini C
    ESMO Open; 2022 Jun; 7(3):100506. PubMed ID: 35696748
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Integrin-targeted quantitative optoacoustic imaging with MRI correlation for monitoring a BRAF/MEK inhibitor combination therapy in a murine model of human melanoma.
    Kazmierczak PM; Burton NC; Keinrath G; Hirner-Eppeneder H; Schneider MJ; Eschbach RS; Heimer M; Solyanik O; Todica A; Reiser MF; Ricke J; Cyran CC
    PLoS One; 2018; 13(10):e0204930. PubMed ID: 30281669
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Relatively mild symptoms after chronic overdose with a double-dose encorafenib: a case report.
    Mian P; Meussen E; Piersma D; Lankheet NAG
    Anticancer Drugs; 2021 Jun; 32(5):589-591. PubMed ID: 33587356
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Treatment experience with encorafenib plus binimetinib for BRAF V600-mutant metastatic melanoma: management insights for clinical practice.
    Augustyn K; Joseph J; Patel AB; Razmandi A; Ali AN; Tawbi HA
    Melanoma Res; 2023 Oct; 33(5):406-416. PubMed ID: 37534686
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Encorafenib and Binimetinib: First Global Approvals.
    Shirley M
    Drugs; 2018 Aug; 78(12):1277-1284. PubMed ID: 30117021
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.